Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial ; volume:18 ; number:1 ; day:6 ; month:8 ; year:2018 ; pages:1-7 ; date:12.2018
BMC cancer ; 18, Heft 1 (6.8.2018), 1-7, 12.2018
- Urheber
-
Papadopoulos, Kyriakos P.
- Beteiligte Personen und Organisationen
-
Ben-Ami, Eytan
Patnaik, Amita
Trone, Denise
Li, Jianke
Demetri, George D.
SpringerLink (Online service)
- DOI
-
10.1186/s12885-018-4692-z
- URN
-
urn:nbn:de:101:1-2018100623160591550313
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Papadopoulos, Kyriakos P.
- Ben-Ami, Eytan
- Patnaik, Amita
- Trone, Denise
- Li, Jianke
- Demetri, George D.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial
Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
Phase I dose-escalation oncology trials with sequential multiple schedules
PK/PD modeling supports the dose-escalation decision in VIKING
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macimorelin in Children with Suspected Growth Hormone Deficiency: An Open-Label, Group Comparison, Dose-Escalation Trial
Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study
A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial
Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
Phase I dose-escalation oncology trials with sequential multiple schedules
PK/PD modeling supports the dose-escalation decision in VIKING
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macimorelin in Children with Suspected Growth Hormone Deficiency: An Open-Label, Group Comparison, Dose-Escalation Trial
Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study
A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial
Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
Phase I dose-escalation oncology trials with sequential multiple schedules
PK/PD modeling supports the dose-escalation decision in VIKING
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macimorelin in Children with Suspected Growth Hormone Deficiency: An Open-Label, Group Comparison, Dose-Escalation Trial
Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study